Instil Bio (TIL) Liabilities and Shareholders Equity (2020 - 2026)

Instil Bio has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $197.7 million in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 14.41% year-over-year to $197.7 million in Q2 2026; TTM through Jun 2026 was $813.4 million, a 19.03% decrease from a year earlier, with the FY2025 full-year figure at $203.5 million, down 22.78% from the prior year.
• Liabilities and Shareholders Equity was $197.7 million for Q2 2026 at Instil Bio, down from $200.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $568.5 million in Q2 2022, with the low at $197.7 million in Q2 2026.
• Average Liabilities and Shareholders Equity over 5 years is $337.1 million, with a median of $300.3 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity slumped 36.13% in 2023, then fell 14.41% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $482.1 million in 2022, then tumbled by 32.46% to $325.6 million in 2023, then retreated by 19.06% to $263.6 million in 2024, then fell by 22.78% to $203.5 million in 2025, then slipped by 2.86% to $197.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $197.7 million (Q2 2026), $200.4 million (Q1 2026), and $203.5 million (Q4 2025), per Business Quant data.